IMMIX BIOPHARMA INC (IMMX) Stock News

USA - Nasdaq - NASDAQ:IMMX - US45258H1068 - Common Stock

6.5 USD

-0.1 (-1.52%)

Last: 12/10/2025, 2:38:49 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

IMMX Latest News, Press Relases and Analysis

All

Press Releases

21 hours ago - By: Immix Biopharma, Inc.

Immix Biopharma Announces Closing of Upsized $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

21 hours ago - By: Immix Biopharma, Inc.

Immix Biopharma Announces Closing of Upsized $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

2 days ago - By: Stocktwits - Mentions: SPY DIA QQQ NFLX ...

Nasdaq, S&P 500 Futures Rise Ahead Of Fed Decision This Week: Why NFLX, CFLT, BA, LLY, IMMX Are On Traders' Radar

3 days ago - By: Immix Biopharma, Inc.

Immix Biopharma Announces Pricing of Upsized $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

3 days ago - By: Immix Biopharma, Inc.

Immix Biopharma Announces Pricing of Upsized $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

3 days ago - By: Immix Biopharma, Inc.

At ASH 2025 Oral Presentation, Immix Biopharma Reports Positive Phase 2 NXC-201 Results, Advancing Toward BLA Submission as a Potentially First- and Best-in-Class Therapy for relapsed/refractory AL Amyloidosis

3 days ago - By: Immix Biopharma, Inc.

At ASH 2025 Oral Presentation, Immix Biopharma Reports Positive Phase 2 NXC-201 Results, Advancing Toward BLA Submission as a Potentially First- and Best-in-Class Therapy for relapsed/refractory AL Amyloidosis

a month ago - By: Benzinga - Mentions: DERM INTS LPTX CMND ...

12 Health Care Stocks Moving In Wednesday's After-Market Session

a month ago - By: Immix Biopharma, Inc.

Immix Biopharma Appoints Chief Commercial Officer to Drive NXC-201 Launch

a month ago - By: Immix Biopharma, Inc.

Immix Biopharma Appoints Chief Commercial Officer to Drive NXC-201 Launch

a month ago - By: Benzinga - Mentions: CDXS WORX IRD SINT ...

12 Health Care Stocks Moving In Friday's After-Market Session

a month ago - By: Immix Biopharma, Inc.

Immix Biopharma’s NXC-201 NEXICART-2 Clinical Trial Results Selected for Oral Presentation at ASH 2025

a month ago - By: Immix Biopharma, Inc.

Immix Biopharma’s NXC-201 NEXICART-2 Clinical Trial Results Selected for Oral Presentation at ASH 2025

2 months ago - By: Immix Biopharma, Inc.

Immix Biopharma to Present at the Guggenheim 2nd Annual Healthcare Innovation Conference

2 months ago - By: Immix Biopharma, Inc.

Immix Biopharma to Present at the Guggenheim 2nd Annual Healthcare Innovation Conference

2 months ago - By: Immix Biopharma, Inc.

Immix Biopharma to Present Abstract at the upcoming ASH 2025 Annual Meeting

2 months ago - By: Immix Biopharma, Inc.

Immix Biopharma to Present Abstract at the upcoming ASH 2025 Annual Meeting

2 months ago - By: Immix Biopharma, Inc.

Immix Biopharma to Present at the 37th Annual Piper Sandler Healthcare Conference

2 months ago - By: Immix Biopharma, Inc.

Immix Biopharma to Present at the 37th Annual Piper Sandler Healthcare Conference

3 months ago - By: Immix Biopharma, Inc.

Immix Biopharma Announces 50% Enrollment Milestone Surpassed in its ongoing relapsed/refractory AL Amyloidosis Clinical Trial, NEXICART-2

3 months ago - By: Immix Biopharma, Inc.

Immix Biopharma Announces 50% Enrollment Milestone Surpassed in its ongoing relapsed/refractory AL Amyloidosis Clinical Trial, NEXICART-2

3 months ago - By: Immix Biopharma, Inc.

Nancy T. Chang, Proven Biotechnology Leader, Joins Immix Biopharma Board of Directors

3 months ago - By: Immix Biopharma, Inc.

Nancy T. Chang, Proven Biotechnology Leader, Joins Immix Biopharma Board of Directors

3 months ago - By: Immix Biopharma, Inc.

Immix Biopharma Announces Strategic Investment by Houston based Goose Capital, led by founding member Dr. Nancy T. Chang

3 months ago - By: Immix Biopharma, Inc.

Immix Biopharma Announces Strategic Investment by Houston based Goose Capital, led by founding member Dr. Nancy T. Chang

4 months ago - By: Immix Biopharma, Inc.

Immix Biopharma to Present at the Stifel 2025 Healthcare Conference

4 months ago - By: Immix Biopharma, Inc.

Immix Biopharma to Present at the Stifel 2025 Healthcare Conference

4 months ago - By: Immix Biopharma, Inc.

Immix Biopharma Announces Other Serious Diseases Strategy

4 months ago - By: Immix Biopharma, Inc.

Immix Biopharma Announces Other Serious Diseases Strategy

5 months ago - By: Immix Biopharma, Inc.

Immix Biopharma Announces Class-Leading Safety Profile, Allowing Potential Future Indication Expansion

5 months ago - By: Immix Biopharma, Inc.

Immix Biopharma Announces Class-Leading Safety Profile, Allowing Potential Future Indication Expansion

5 months ago - By: Immix Biopharma, Inc.

Immix Biopharma Announces Accelerated NEXICART-2 Clinical Trial Progress in relapsed/refractory AL Amyloidosis

5 months ago - By: Immix Biopharma, Inc.

Immix Biopharma Announces Accelerated NEXICART-2 Clinical Trial Progress in relapsed/refractory AL Amyloidosis

6 months ago - By: Zacks Investment Research

Immix Biopharma (IMMX) Upgraded to Buy: What Does It Mean for the Stock?

6 months ago - By: Immix Biopharma, Inc.

Immix Biopharma Attends FDA CEO Forum in Washington DC

6 months ago - By: Immix Biopharma, Inc.

Immix Biopharma Attends FDA CEO Forum in Washington DC

6 months ago - By: Yahoo Finance - Mentions: RMBS ONC SERV UBER ...

H.C. Wainwright Reiterates Buy Rating on Immix Biopharma (IMMX) Following Promising Interim Results from NXC-201 Trial

6 months ago - By: Immix Biopharma, Inc.

Immix Biopharma Announces Primary Endpoint Met in positive NXC-201 Interim Results Presented at ASCO, Enabling Path to Best-in-Class Therapy for relapsed/refractory AL Amyloidosis

6 months ago - By: Immix Biopharma, Inc.

Immix Biopharma Announces Primary Endpoint Met in positive NXC-201 Interim Results Presented at ASCO, Enabling Path to Best-in-Class Therapy for relapsed/refractory AL Amyloidosis